SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-333824"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-333824" > The role of infecti...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005343naa a2200553 4500
001oai:DiVA.org:uu-333824
003SwePub
008171129s2017 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3338242 URI
0247 a https://doi.org/10.1007/s00134-017-4780-62 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
1001 a Tängdén, Thomasu Uppsala universitet,Infektionssjukdomar4 aut0 (Swepub:uu)thota437
2451 0a The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections
264 c 2017-04-13
264 1b Springer Science and Business Media LLC,c 2017
338 a print2 rdacarrier
520 a Critically ill patients with severe infections are at high risk of suboptimal antimicrobial dosing. The pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobials in these patients differ significantly from the patient groups from whose data the conventional dosing regimens were developed. Use of such regimens often results in inadequate antimicrobial concentrations at the site of infection and is associated with poor patient outcomes. In this article, we describe the potential of in vitro and in vivo infection models, clinical pharmacokinetic data and pharmacokinetic/ pharmacodynamic models to guide the design of more effective antimicrobial dosing regimens. Individualised dosing, based on population PK models and patient factors (e.g. renal function and weight) known to influence antimicrobial PK, increases the probability of achieving therapeutic drug exposures while at the same time avoiding toxic concentrations. When therapeutic drug monitoring (TDM) is applied, early dose adaptation to the needs of the individual patient is possible. TDM is likely to be of particular importance for infected critically ill patients, where profound PK changes are present and prompt appropriate antibiotic therapy is crucial. In the light of the continued high mortality rates in critically ill patients with severe infections, a paradigm shift to refined dosing strategies for antimicrobials is warranted to enhance the probability of achieving drug concentrations that increase the likelihood of clinical success.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a Individualised dosing
653 a Antibiotics
653 a Pharmacokinetics
653 a Pharmacodynamics
653 a Mathematical modelling
7001 a Martin, V. Ramosu Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.4 aut
7001 a Felton, T. W.u Univ South Manchester Hosp, Intens Care Unit, Manchester, Lancs, England.4 aut
7001 a Nielsen, Elisabet I.,d 1973-u Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)elnie838
7001 a Marchand, S.u INSERM, Pole Biol St, U1070, Poitiers, France.;Univ Poitiers, UFR Med Pharm, Poitiers, France.4 aut
7001 a Brueggemann, R. J.u Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands.4 aut
7001 a Bulitta, J. B.u Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Orlando, FL USA.4 aut
7001 a Bassetti, M.u Santa Maria Misericordia Univ Hosp, Div Infect Dis, Udine, Italy.;Univ Udine, Udine, Italy.4 aut
7001 a Theuretzbacher, U.u Ctr Anti Infect Agents, Vienna, Austria.4 aut
7001 a Tsuji, B. T.u SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA.4 aut
7001 a Wareham, D. W.u Queen Mary Univ London, Barts & London Sch Med & Dent, Antimicrobial Res Grp, London, England.4 aut
7001 a Friberg, Lena Eu Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo
7001 a De Waele, J. J.u Ghent Univ Hosp, Dept Crit Care Med, Ghent, Belgium.4 aut
7001 a Tam, V. H.u Univ Houston, Coll Pharm, Dept Pharm Practice & Translat Res, Houston, TX USA.4 aut
7001 a Roberts, Jason A.u Univ Queensland, Trauma & Crit Care Res Ctr, Burns, Brisbane, Qld, Australia.;Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Brisbane, Qld, Australia.;Royal Brisbane & Womens Hosp, Dept Intens Care Med & Pharm, Level 3,Ned Hanlon Bldg, Brisbane, Qld 4029, Australia.4 aut
7102 a Uppsala universitetb Infektionssjukdomar4 org
7730 t Intensive Care Medicined : Springer Science and Business Media LLCg 43:7, s. 1021-1032q 43:7<1021-1032x 0342-4642x 1432-1238
8564 u https://www.research.manchester.ac.uk/portal/en/publications/the-role-of-infection-models-and-pkpd-modelling-for-optimising-care-of-critically-ill-patients-with-severe-infections(ef63d68d-b9bf-4957-8181-85a2b18ecb81).html
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-333824
8564 8u https://doi.org/10.1007/s00134-017-4780-6

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy